Table 2 Comparison of patients who were prescribed antiosteoporosis medication and those who were not.
From: Long-term persistence of treatment after hip fracture in a fracture liaison service
No prescription | Prescription at any time | OR (95% CI) | p | Model OR (95% CI) | p | |
|---|---|---|---|---|---|---|
(n = 89) | (n = 283) | |||||
Age (years), mean (SD) | 81.0 (8.5) | 78.9 (9.0) | 0.97 (0.95–1.00) | 0.054 | 0.94 (0.90–0.99) | 0.001 |
Sex (female), n (%) | 55 (61.8) | 228 (80.5) | 2.56 (1.52–4.31) | 0.0001 | 1.72 (0.79–3.74) | 0.168 |
Identification of patients, n (%) | ||||||
Emergency registry | 54 (60.6) | 163 (57.6) | 0.55 (0.18–1.66) | 0.289 | ||
Admission (hip fracture) | 31 (34.8) | 98 (34.6) | 0.57 (0.18–1.80) | 0.341 | ||
Attended < 12 weeks after the fracture | 32 (35.9) | 113 (39.9) | 1.16 (0.71–1.91) | 0.55 | ||
Previous fracture, n (%) | 10 (11.2) | 67 (23.6) | 2.45 (1.20–5.00) | 0.014 | ||
Previous treatment with bisphosphonates, n (%)a | 2 (2.2) | 51 (18.0) | 9.58 (2.28–40.19) | 0.002 | 9.94 (1.29–76.32) | 0.027 |
Lumbar T score, mean (SD) | − 1.38 (1.6) | − 2.05 (1.6) | 0.78 (0.64–0.95) | 0.014 | 0.80 (0.65–0.99) | 0.039 |
Densitometry result; osteoporosis, n (%)a | 22 (24.7) | 92 (32.5) | 1.89 (1.00–3.59) | 0.05 | ||
FRAX major, mean (SD) | 19.0 (10.2) | 16.4 (9.9) | 1.03 (1.00–1.05) | 0.04 | ||
Referral to primary care after baseline visit, n (%) | 79 (88.7) | 237 (83.7) | 0.64 (0.31–1.32) | 0.22 | ||
